Investors Urged to Take Action Following Significant Price Target Cut for Aquestive Therapeutics

Investor Alert: Price Target Cut and Its Implications

In early January 2026, investors in Aquestive Therapeutics, Inc. faced unexpected news when Cantor Fitzgerald significantly reduced its price target for the company from $15 to $8. This stark decrease was not just a reassessment of the stock's value but also a warning regarding potential delays in the FDA approval process for its drug Anaphylm. The announcement highlighted increasing concerns about the risk of receiving a Complete Response Letter (CRL), a scenario that could hamper the company’s operations further.

The Background of the Situation

Shares of Aquestive Therapeutics, traded under the NASDAQ ticker AQST, plummeted from $6.21 to $3.91 following the FDA's identification of deficiencies in the company’s New Drug Application (NDA) for Anaphylm. The swift decline resulted in significant losses for shareholders, with estimates indicating over 37% of their investment value diminished in a single trading day. Those who bought into AQST stock between June 16, 2025, and January 8, 2026, have been notably affected, with financial repercussions that have driven many to consider legal action.

Analyst Forecasts: Turning Point for Investors

Before this setback, analysts had maintained an optimistic outlook about the FDA's review process. They relied on assurances from Aquestive management that the approval was on track, with the commercial launch of Anaphylm expected in early 2026. Despite the analysts' initial confidence, the January 9 announcement led to a rapid reassessment across Wall Street, culminating in a series of downgrades that illustrated the disconnect between management’s projections and the reality presented by the regulatory body.

Among the most significant downgrades was Cantor's, which assessed the potential for a CRL as a risky and costly setback, prompting a 47% reduction in their price target. Similarly, Oppenheimer labeled the FDA's communication as a "meaningful setback" and projected three potential scenarios for AQST, one of which suggested that shares could dip below $1.

The Dangers of Misinformation

The unfolding circumstances underscore an essential principle for investors: the value of honest and transparent communication from company management. When analysts base their expectations on what they believe are company disclosures, any misrepresentation can lead to devastating financial outcomes. Joseph E. Levi, Esq., an attorney representing aggrieved shareholders, emphasized, "When analyst expectations are built on incomplete or misleading company disclosures, the resulting corrections can cause significant investor harm."

This situation serves as a cautionary tale, highlighting the importance of aligning company messaging with actual developments to prevent drastic market reactions.

Take Action: Legal Recourse for Affected Investors

For investors seeking to recover their losses, the window for leading a potential class-action lawsuit is open until May 4, 2026. Engaging legal representation could provide an avenue to recapture some of the lost investments. Interested individuals can connect with Joseph E. Levi, Esq. at Levi & Korsinsky, LLP, where they can learn about their options and how to potentially join the class action effort.

As this case develops, it serves as a vital reminder about the interconnectedness of investor trust, corporate communications, and market valuations, which are all crucial elements in maintaining a healthy business ecosystem.